[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-359592-105":59,"doc-detail-359592-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","carbonic-anhydrase-9-as-a-circulating-biomarker-and-therapeutic-target-atezolizumab-plus-bevacizumab-in-hepatocellular-carcinoma","Carbonic anhydrase 9 as a circulating biomarker and therapeutic target - Atezolizumab plus bevacizumab in hepatocellular carcinoma","","Atezolizumab plus bevacizumab (Atez/Bev) is established first-line therapy for unresectable hepatocellular carcinoma, yet reliable biomarkers predicting response remain limited. This study uses high-throughput plasma proteomics with Olink proximity extension assay in discovery and validation cohorts to identify predictive factors. Carbonic anhydrase 9 (CA9) was assessed by transcriptomic and single-cell analyses, and causality tested in a syngeneic mouse model, showing tumor-derived circulating CA9 drives resistance by shaping immunosuppressive, angiogenic tumor microenvironments and can be countered by CA9 inhibition.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/carbonic-anhydrase-9-as-a-circulating-biomarker-and-therapeutic-target-atezolizumab-plus-bevacizumab-in-hepatocellular-carcinoma/359592/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/carbonic-anhydrase-9-as-a-circulating-biomarker-and-therapeutic-target-atezolizumab-plus-bevacizumab-in-hepatocellular-carcinoma/359592.png","ImageObject",300,407,{"name":92,"@type":93},"Sophia Brooks","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are biomarkers needed for unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab?","Question",{"text":112,"@type":113},"Atez/Bev is first-line therapy, but a substantial portion of patients develop primary or acquired resistance. Tissue sampling is often not feasible, so minimally invasive biomarkers that predict response are urgently needed.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was circulating carbonic anhydrase 9 (CA9) identified in this study?",{"text":117,"@type":113},"Discovery used high-throughput plasma proteomic screening with the Olink proximity extension assay in 78 patients. Validation was performed in an independent cohort of 89 patients, and tumorous CA9 was evaluated using transcriptomic and single-cell analyses.",{"name":119,"@type":110,"acceptedAnswer":120},"What did functional studies show about CA9’s role in treatment resistance?",{"text":121,"@type":113},"In a syngeneic mouse model, tumors overexpressing CA9 were resistant to Atez/Bev. Resistance was associated with reduced CD8+ T cell infiltration, suppressed cytotoxic gene expression, enrichment of M2-like macrophages, and pro-angiogenic signaling. Adding a CA9 inhibitor reversed this resistance and restored antitumor efficacy.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},359592,1790169172,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962084925636,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Open access Original research  \nCarbonic anhydrase 9 as a circulating biomarker and therapeutic target inpatients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab  \nYu Sato  ,1 Takahiro Kodama  ,1 Kazuki Maesaka,1 Machiko Kai,1 Kazuhiro Murai  ,1 Yuki Tahata,1 Yoshinobu Saito,1 Tasuku Nakabori  ,2 Kazuyoshi Ohkawa,2 Satoshi Tanaka,3 Ryotaro Sakamori,3 Masanori Miyazaki,4 Kunimaro Furuta,5 Hisashi Ishida,5 Kengo Matsumoto,6 Seiichi Tawara  ,7 Takayuki Yakushijin,7 Yasutoshi Nozaki,8 Atsushi Hosui,9 Akira Nishio  ,10 Nobuyuki Tatsumi,10 Naruyasu Kakita,11 Changhoon Yoo,12 Moto Fukai,13 Akinobu Taketomi,13 Hayato Hikita,1 Tomohide Tatsumi,1 Tetsuo Takehara14  \nTo cite: Sato Y, Kodama T, Maesaka K, et al. Carbonic anhydrase 9 as a circulating biomarker and therapeutic target in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab. Journal for ImmunoTherapy of Cancer 2026;14:e013384 . doi:10 . 1136/ jitc-2025-013384  \n► Additional supplemental material is published online only. To view, please visit the journal online ([https://doi.org/10.1136/](https://doi.org/10.1136/)[ ](https://doi.org/10.1136/)[jitc-2025-013384](jitc-2025-013384)) .  \nYS and TK contributed equally. YS and TK are joint first authors. Accepted 16 March 2026  \n© Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.  \nFor numbered affiliations see end of article.  \nCorrespondence to  \nDr Takahiro Kodama; [t-kodama@gh.med.osaka-u](t-kodama@gh.med.osaka-u). [ac.jp](ac.jp)  \nABSTRACT  \nBackground Atezolizumab plus bevacizumab (Atez/ Bev) has become the first-line therapy for unresectable hepatocellular carcinoma (HCC) . However, reliable biomarkers to predict therapeutic response remain lacking.  \nMethods We conducted a high-throughput plasma proteomic screen using the Olink proximity extension assay to identify predictive biomarkers in 78 patients with unresectable HCC treated with Atez/Bev. Validation was performed in an independent cohort of 89 patients. Tumorous expression of the lead candidate, carbonic anhydrase 9 (CA9), was examined using transcriptomicand single-cell analyses. Functional studies were performed in a syngeneic mouse model using Car9-overexpressing hepatoma cells, treated with antiprogrammed death-ligand 1/vascular endothelial growth factor antibodies, with or without a CA9 inhibitor.  \nResults High plasma CA9 levels were significantly associated with poor objective response rate, disease control rate, progression-free survival, and overall survival in both discovery and validation cohorts. Multivariable analysis confirmed CA9 as an independent predictor of treatment resistance and poor outcomes. Tumorous CA9 expression correlated strongly with circulating CA9 and was restricted to malignant cells. In vivo, tumors overexpressing Car9 showed resistance to Atez/Bev therapy, characterized by reduced CD8+T cell infiltration, suppressed cytotoxic gene expression, enrichment of M2-like macrophages, and pro-angiogenic signaling. The addition of a CA9 inhibitor reversed resistance and restored antitumor efficacy of Atez/Bev in this model.  \nConclusions Tumor-derived circulating CA9 is a predictive biomarker and functional driver of resistance to Atez/Bev therapy in HCC. Targeting CA9 may enhance therapeutic response.  \nWHAT IS ALREADY KNOWN ON THIS TOPIC  \n⇒ Combination immunotherapy with atezolizumaband bevacizumab (Atez/Bev) is the current first-line systemic therapy for unresectable hepatocellular carcinoma (HCC) . However, a substantial proportion of patients exhibit primary or acquired resistance. While tumor immune microenvironment characteristics such as CD8+T cell infiltration or regulatory T-cell exclusion have been linked to treatment response, tissue sampling is often not feasible in clinical practice. Therefore, the development of minimally invasive and clinically applicable biomarkers to predict re","cbCaiqAAHWPJnxmK","https://ap.wps.com/l/cbCaiqAAHWPJnxmK","pdf",4125539,14,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# What Is Already Known on This Topic\n# Background\n# What This Study Adds\n# How This Study Might Affect Research, Practice or Policy","[{\"question\":\"Why are biomarkers needed for unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab?\",\"answer\":\"Atez/Bev is first-line therapy, but a substantial portion of patients develop primary or acquired resistance. Tissue sampling is often not feasible, so minimally invasive biomarkers that predict response are urgently needed.\"},{\"question\":\"How was circulating carbonic anhydrase 9 (CA9) identified in this study?\",\"answer\":\"Discovery used high-throughput plasma proteomic screening with the Olink proximity extension assay in 78 patients. Validation was performed in an independent cohort of 89 patients, and tumorous CA9 was evaluated using transcriptomic and single-cell analyses.\"},{\"question\":\"What did functional studies show about CA9’s role in treatment resistance?\",\"answer\":\"In a syngeneic mouse model, tumors overexpressing CA9 were resistant to Atez/Bev. Resistance was associated with reduced CD8+ T cell infiltration, suppressed cytotoxic gene expression, enrichment of M2-like macrophages, and pro-angiogenic signaling. Adding a CA9 inhibitor reversed this resistance and restored antitumor efficacy.\"}]","Carbonic anhydrase 9 as a circulating biomarker and therapeutic target - Atezolizumab plus bevacizumab in hepatocellular carcinoma | PDF",1790137240,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4852cde5b8eff8cd1e9ffaae27fff4d4.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8f33d8ca45e9af9d4d0169fa0b488251.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7eaf6aa8658a1030045f3f4fb1f3dfb3.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7d5413b319ab49a240e509bb8df62422.webp",980,1306]